Search Results - Andrea Rubbert-Roth

Refine Results
  1. 1
    Assessing the safety of biologic agents in patients with rheumatoid arthritis

    Assessing the safety of biologic agents in patients with rheumatoid arthritis by Andrea Rubbert‐Roth

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

    Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review by Andrea Rubbert‐Roth, Axel Finckh

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

    A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases by Andrea Rubbert‐Roth, Daniel E. Furst, Jan Michael Nebesky, Angela Jin, Erhan Berber

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

    Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis by Andrea Rubbert‐Roth, Nicolas Vuilleumier, Burkhard Ludewig, K. Schmiedeberg, Christoph Haller, Johannes von Kempis

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases

    Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases by Olaf Schultz, F. Oberhäuser, Jasemine Saech, Andrea Rubbert‐Roth, Moritz Hahn, Wilhelm Krone, Matthias Laudes

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

    Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life stud... by Gerd R Burmester, Eugen Feist, H. Kellner, Jürgen Braun, Christof Iking‐Konert, Andrea Rubbert‐Roth

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY

    AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GRO... by Andrea Rubbert‐Roth, J. Sparks, A. Constantin, Ricardo Machado Xavier, Y. Song, J. Suboticki, R Fleischmann

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    POS0693 IMPACT OF UPADACITINIB VERSUS ABATACEPT ON INDIVIDUAL DISEASE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSES TO BIOLOGIC DMARDS

    POS0693 IMPACT OF UPADACITINIB VERSUS ABATACEPT ON INDIVIDUAL DISEASE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSES TO BIOLOGIC DMARDS by R. Van Vollenhoven, Andrea Rubbert‐Roth, S. Hall, Ricardo Machado Xavier, A. Shmagel, Yan Song, S. Anyanwu, Vibeke Strand

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study

    Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study by Andrea Rubbert‐Roth, Koji Kato, Boulos Haraoui, Maureen Rischmueller, Yanxi Liu, Nasser Khan, Heidi S. Camp, Ricardo Machado Xavier

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab

    Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab by Andrea Rubbert‐Roth, Anthony Sebba, Laura Brockwell, Ariella Kelman, Benjamin Porter-Brown, Jennifer Pulley, Pavel Napalkov, Ronald van Vollenhoven

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

    Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) by Andrea Rubbert‐Roth, P. P. Tak, Cristiano A. F. Zerbini, Jean-Luc Tremblay, Luis Carreño, G. Armstrong, Neil Collinson, T. Shaw

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

    Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial by Gerd R Burmester, William F. C. Rigby, Ronald van Vollenhoven, Jonathan Kay, Andrea Rubbert‐Roth, Ariella Kelman, Sophie Dimonaco, Nina Mitchell

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial

    Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results... by Gerd R Burmester, William F. C. Rigby, Ronald van Vollenhoven, Jonathan Kay, Andrea Rubbert‐Roth, Ricardo Blanco, Alysha Kadva, Sophie Dimonaco

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

    Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis by Andrea Rubbert‐Roth, Jeffrey Enejosa, Aileen L. Pangan, Boulos Haraoui, Maureen Rischmueller, Nasser Khan, Ying Zhang, Naomi Martin, Ricardo Machado Xavier

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    POS0671 CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS BY TYPE OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG: DATA FROM THE PHASE 3 SELECT-CHOICE STUDY

    POS0671 CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS BY TYPE OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG: DATA FROM THE PHASE 3... by Andrea Rubbert‐Roth, Ricardo Machado Xavier, Boulos Haraoui, Herbert S. B. Baraf, Maureen Rischmueller, Naomi Martin, Yong Song, J. Suboticki, J. Cush

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

    Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective p... by P. Emery, P. J. Mease, Andrea Rubbert‐Roth, Jeffrey R. Curtis, Ulf Müller‐Ladner, Norman Gaylis, S. Williams, M. Reynard, Helen E.J. Tyrrell

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    POS0677 CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS

    POS0677 CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS by Andrea Rubbert‐Roth, B. Combe, Z. Szekanecz, S. Hall, B. Haraoui, S. Attar, A. K. H. Ekwall, Y. Song, T. Shaw, O. Nagy, Ricardo Machado Xavier

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS

    POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS by Gerd R Burmester, J. Stigler, Andrea Rubbert‐Roth, Yoshiya Tanaka, Valderílio Feijó Azevedo, Dane Coombs, R. Mccaskill, Roger Lippé, Peter Wung, Lianne S. Gensler

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts

    Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts by Ruediger B. Müeller, Caroline Hasler, Florian Popp, Frederik Mattow, Mirsada Durmisi, Alexander Souza, Paul Hasler, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Johannes von Kempis

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS

    POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS by Roy Fleischmann, Louis Bessette, J. Sparks, S. Hall, Manish Jain, Adriana María Kakehasi, Y. Song, Sebastian Meerwein, Ryan DeMasi, J. Suboticki, Andrea Rubbert‐Roth

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: